Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Forte Biosciences Inc (NQ: FBRX )

4.180 -0.270 (-6.07%)
Streaming Delayed Price Updated: 1:19 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Forte Biosciences Inc

< Previous 1 2 Next >
Forte Biosciences, Inc. Announces Second Quarter 2024 Results and Provides Business Update
From Forte Biosciences, Inc.
Via Business Wire
Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules
From Forte Biosciences, Inc.
Via Business Wire
Forte Biosciences, Inc. Announces First Quarter 2024 Results and Provides Business Update
From Forte Biosciences, Inc.
Via Business Wire
Forte Biosciences, Inc. Announces 2023 Results and Provides Business Update
From Forte Biosciences, Inc.
Via Business Wire
Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules
From Forte Biosciences, Inc.
Via Business Wire
Forte Biosciences, Inc. Announces Third Quarter 2023 Results and Provides Business Update
From Forte Biosciences, Inc.
Via Business Wire
ISS and Glass Lewis Recommend Forte Biosciences Stockholders Vote FOR Boardroom Change at the Company’s Upcoming Annual Meeting
From On behalf of Concerned Stockholders of Forte
Via Business Wire
Concerned Stockholders of Forte Biosciences and Its Independent Director Candidates Share Key Facts that Reinforce the Need for Urgent Change in the Company’s Boardroom
From On behalf of Concerned Stockholders of Forte
Via Business Wire
Concerned Stockholders of Forte Biosciences File Definitive Proxy Statement and Send Letter to Stockholders
From On behalf of Concerned Stockholders of Forte
Via Business Wire
Forte Biosciences, Inc. Announces Second Quarter 2023 Results and Provides Business Update
From Forte Biosciences, Inc.
Via Business Wire
Forte Biosciences, Inc. Announces $25 Million Financing and R&D Update for FB-102
From Forte Biosciences, Inc.
Via Business Wire
Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules
From Forte Biosciences, Inc.
Via Business Wire
Forte Biosciences, Inc. Announces First Quarter 2023 Results and Provides Business Update
From Forte Biosciences, Inc.
Via Business Wire
Forte Biosciences, Inc. Announces Full Year 2022 Results and Provides Business Update
From Forte Biosciences, Inc.
Via Business Wire
Mr. David Gryska Appointed to Forte Biosciences Board of Directors
From Forte Biosciences, Inc.
Via Business Wire
Forte Biosciences, Inc. Announces Third Quarter 2022 Results and Provides Business Update
From Forte Biosciences, Inc.
Via Business Wire
Dr. Scott Brun, M.D. Appointed to Forte Biosciences Board of Directors
From Forte Biosciences, Inc.
Via Business Wire
Camac Partners Condemns Forte Biosciences’ Seemingly Defensive and Unjustifiable Capital Raise
From Camac Partners, LLC
Via Business Wire
Forte Biosciences, Inc. Announces Second Quarter 2022 Results and Provides Business Update
From Forte Biosciences, Inc.
Via Business Wire
Forte Biosciences, Inc. Announces the Appointment of Dr. Hubert Chen, MD as Chief Scientific Officer and President
From Forte Biosciences, Inc.
Via Business Wire
Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules
From Forte Biosciences, Inc.
Via Business Wire
Forte Biosciences, Inc. Announces First Quarter 2022 Results and Provides Business Update
From Forte Biosciences, Inc.
Via Business Wire
Forte Biosciences, Inc. (NASDAQ:FBRX) Shareholder Notice: Investigation over Potential Wrongdoing
San Diego, CA -- (SBWIRE) -- 10/27/2021 -- An investigation was announced over potential breaches of fiduciary duties by certain directors at Forte Biosciences, Inc. 
Via SBWire
NASDAQ:FBRX Shareholder Notice: Investigation over Potential Securities Laws Violations by Forte Biosciences, Inc.
San Diego, CA -- (SBWIRE) -- 09/17/2021 -- Forte Biosciences, Inc is under investigation concerning potential securities laws violations in connection with certain financial statements. 
Via SBWire
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Forte Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Forte Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
INVESTIGATION REMINDER: The Schall Law Firm Announces It Is Investigating Claims Against Forte Biosciences, Inc. and Encourages Investors With Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
Clinical Trial of FB-401 For the Treatment of Atopic Dermatitis Fails to Meet Statistical Significance
From Forte Biosciences, Inc.
Via Business Wire
Forte Biosciences, Inc. to Review the Second Quarter 2021 Results and Expects to Announce Topline Data From Phase 2 Clinical Trial of FB-401 for the Treatment of Atopic Dermatitis on Sept. 7
From Forte Biosciences, Inc.
Via Business Wire
Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules
From Forte Biosciences, Inc.
Via Business Wire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.